![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral load <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real World Effectiveness
|
|
|
Reported by Jules Levin
DDW May 22-24 San Diego, CA
K Kowdley1, P Ruane2, D Ain2, P Ingiliz3, S Mauss4, P Buggisch5, J Petersen5,
N Tsai6, Y Lee7, M Natha8, E Eggleton8, B Kreter8, DM Brainard8, M Curry9
1Swedish Medical Seattle, WA; 2Ruane Medical and Liver Health, Los Angeles, CA; 3Medizinisches Infektiologie Zentrum Berlin, Berlin; 4Center for HIV and Hepatogastroenterology, Duesseldorf; 5IFI Institut für Interdisziplinäre Medizin, Asklepios Klinik St. Georg, Hamburg Germany; 6Queens Medical Center, UH, Honolulu Hawaii; 7TRIO Health Analytics; 8Gilead Sciences Foster City, CA; 9Beth Israel, Boston, MA
![EASL1](../images/060616/060616-2/EASL1.gif)
![EASL2](../images/060616/060616-2/EASL2.gif)
![EASL3](../images/060616/060616-2/EASL3.gif)
![EASL4](../images/060616/060616-2/EASL4.gif)
![EASL5](../images/060616/060616-2/EASL5.gif)
![EASL6](../images/060616/060616-2/EASL6.gif)
![EASL7](../images/060616/060616-2/EASL7.gif)
![EASL8](../images/060616/060616-2/EASL8.gif)
![EASL9](../images/060616/060616-2/EASL9.gif)
![EASL10](../images/060616/060616-2/EASL10.gif)
![EASL11](../images/060616/060616-2/EASL11.gif)
![EASL12](../images/060616/060616-2/EASL12.gif)
![EASL13](../images/060616/060616-2/EASL13.gif)
![EASL14](../images/060616/060616-2/EASL14.gif)
![EASL15](../images/060616/060616-2/EASL15.gif)
![EASL16](../images/060616/060616-2/EASL16.gif)
![EASL17](../images/060616/060616-2/EASL17.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|